RT Journal Article
SR Electronic
T1 Tumor-specific activity of precision medicines in the NCI-MATCH trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.30.23287951
DO 10.1101/2023.03.30.23287951
A1 Zhou, Ivvone
A1 Plana, Deborah
A1 Palmer, Adam C.
YR 2023
UL http://medrxiv.org/content/early/2023/03/31/2023.03.30.23287951.abstract
AB Background NCI-MATCH is a precision medicine basket trial designed to test the effectiveness of treating cancers based on specific genetic changes in patients’ tumors, regardless of cancer type. Multiple subprotocols have each tested different targeted therapies matched to specific genetic aberrations. Most subprotocols exhibited low rates of tumor shrinkage as evaluated across all tumor types enrolled. We hypothesized that these results may arise because these precision cancer therapies have tumor type-specific efficacy, as is common among other cancer therapies.Methods To test the hypothesis that certain tumor types are more sensitive to specific therapies than other tumor types, we applied permutation testing to tumor volume change and progression-free survival data from ten published NCI-MATCH subprotocols (together n=435 patients). False discovery rate was controlled by the Benjamini-Hochberg procedure.Results Six of ten subprotocols exhibited statistically significant evidence of tumor-specific drug sensitivity, four of which were previously considered negative based on response rate across all tumors. This signal-finding analysis highlights potential uses of FGFR tyrosine kinase inhibition in urothelial carcinomas with actionable FGFR aberrations, MEK inhibition in lung cancers with BRAF non-V600E mutations, and MEK inhibition in cholangiocarcinomas with NRAS mutations.Conclusions These findings support the value of basket trials because even when precision medicines do not have tumor-agnostic activity, basket trials can identify tumor-specific activity for future study.Competing Interest StatementA.C.P. has received consulting fees from Merck, AstraZeneca, Kymera, and research funding from Prelude Therapeutics. A.C.P. declares that these relationships are not related to the content of this manuscript.Funding StatementD.P. is supported by NIGMS grant T32-GM007753 and F30-CA260780.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We analyze published data from published trials. All citations are included in this article's reference lists. This does not involve any form of data access or download from a source other than the contents of published articles.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data analyzed in the present work was previously published, as cited.